Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101 in exchange for EUR 2.5 million upfront payment, milestone payments and royalties on future sales of IPH 2101. In addition, Novo Nordisk receives fully paid-up exclusive rights to NN8555/IPH 2301.
Novo Nordisk and Innate Pharma swap product rights
Posted by worldpharmanews 697 days ago (http://www.worldpharmanews.com)Who Voted for this Story
Comments